⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947772 | 0.97 | — | — | |
| SCHEMBL22335953 | 0.83 | — | — | |
| SCHEMBL6484347 | 0.77 | HTT (0.37) | — | |
| SCHEMBL15285084 | 0.75 | — | — | |
| SCHEMBL19658584 | 0.73 | — | — | |
| SCHEMBL12640036 | 0.73 | MMP13 (0.34) | — | |
| SCHEMBL26845347 | 0.69 | — | — | |
| SCHEMBL18361635 | 0.69 | VNN1 (0.39) | — | |
| SCHEMBL17784152 | 0.68 | SCN9A (0.38) | — | |
| SCHEMBL101485 | 0.68 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4608389-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | Nine Square Therapeutics Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024092235-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20220348559-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3317269-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| WO-2014065791-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |